Results 231 to 240 of about 754,856 (314)

Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery. [PDF]

Proc Natl Acad Sci U S A
Davey SD, Forde-Thomas JE, Hulme BJ, Lees K, Costain AH, Evans M, Rinaldi G, Frame L, Stojanovski L, Simeons FRC, Tavendale A, MacLeod AK, Pichon R, Lee YH, Polak O, Chalmers IW, Dankwa B, Odhiambo BK, Guimaraes VH, Hegarty M, Swain MT, Aubrey W, Caldwell N, MacDonald AS, Gilbert IH, Baragaña B, Read KD, Hoffmann KF.   +27 more
europepmc   +1 more source

Mechanism‐informed machine learning for individualized tacrolimus dose adjustment in the early post‐kidney transplant period

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus dosing in the early post‐kidney transplant period is challenging due to a narrow therapeutic index and substantial interindividual pharmacokinetic (PK) variability. This study aimed to develop and validate mechanism‐informed machine learning (ML) models to support individualized tacrolimus dosing during this critical period ...
Hui Yu, Zihan Qin, Logan S. Smith, Jeong M. Park, Hao‐Jie Zhu   +4 more
wiley   +1 more source

Draft genome sequence of <i>Nonomuraea bangladeshensis</i> strain B208 with high potential for specific cytochrome P450 monooxygenases. [PDF]

Microbiol Resour Announc
Suenaga H, Miyazaki K, Fukushima T.
europepmc   +1 more source

Tacrolimus exposure during pregnancy in kidney and liver transplantation recipients: A comparison between whole blood and plasma concentration‐to‐dose ratios

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus monitoring is generally performed in whole blood (WB). Most (>85%) of circulating tacrolimus is bound to red blood cells. During pregnancy, WB monitoring might be suboptimal because of physiological changes including increased plasma volume and decreased haematocrit.
Jildau R. Meinderts, Paola Mian, Frederike G. I. van Vilsteren, Karien M. H. van de Wetering, Jelmer R. Prins, Stefan P. Berger, Daan J. Touw, Margriet F. C. de Jong   +7 more
wiley   +1 more source

Navigating Cetacean Mitochondrial Genome Data: Identifying Coverage and Deficiencies in Public Repositories. [PDF]

Mol Ecol Resour
Afonso L, Lagrotteria A, Lavrador AS, Suarez-Bregua P, Álvarez-González M, Valente R, Jensen MR, Saavedra C, Morais DK, Sousa-Pinto I, Pierce GJ, Magalhães C, Correia AM.   +12 more
europepmc   +1 more source

Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells

British Journal of Clinical Pharmacology, EarlyView.
Common genetic CYP2B6 variants correlate with adverse breast cancer outcome. The oestrogen metabolites estriol and 16‐epiestriol, which are formed downstream of CYP2B6‐catalysed 16α/β‐hydroxytestosterone, may be linked to elevated breast cancer risk and might increase due to the demonstrated CYP2B6 variants‐related metabolic shifts.
Marco Hoffmann, Julian Peter Müller, Stefan Düsterhöft, Sabrina Yamoune, Katja Susanne Just, Julia Carolin Stingl   +5 more
wiley   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

Automated High-Throughput Raman Spectral Framework for Cellular Differentiation Monitoring. [PDF]

Nano Lett
Raj P, Li M, Ueyama-Toba Y, Mizuguchi H, Fujita K, Barman I.   +5 more
europepmc   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source